Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple

Michael Forte1, Bruce G Gold, Gail Marracci

  • 1Vollum Institute, Oregon Health and Science University, Portland, OR 97239, USA. forte@ohsu.edu

Insights

Multiple sclerosis (MS) involves axonal damage, potentially driven by mitochondrial dysfunction. Targeting cyclophilin D (CyPD) and the mitochondrial permeability transition pore (PTP) may offer neuroprotective therapies for MS patients.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Multiple sclerosis (MS) is a primary cause of neurological disability in young adults, affecting 2 million globally.
  • Traditionally viewed as inflammatory, MS is increasingly recognized as neurodegenerative, involving axonal injury and CNS atrophy.
  • The molecular mechanisms driving progressive axonal loss in MS remain poorly understood.

Purpose of the Study:

  • To investigate the role of mitochondrial dysfunction in MS-related axonal damage.
  • To explore cyclophilin D (CyPD) and the mitochondrial permeability transition pore (PTP) as potential therapeutic targets.

Main Methods:

  • Utilized a murine model of MS, experimental autoimmune encephalomyelitis (EAE).
  • Compared disease progression and axonal preservation in wild-type (WT) mice and mice lacking CyPD (CyPD-knockout).
  • Assessed neuronal resistance to oxidative stress and mitochondrial calcium handling in CyPD-knockout neurons and mitochondria.

Main Results:

  • CyPD-knockout mice with EAE showed partial recovery and significantly preserved axons despite comparable inflammation levels to WT mice.
  • Neurons from CyPD-knockout animals exhibited resistance to reactive oxygen and nitrogen species implicated in axonal damage.
  • Mitochondria lacking CyPD demonstrated a greater capacity for calcium sequestration.

Conclusions:

  • Pathological activation of the mitochondrial PTP is directly implicated in axonal damage during MS.
  • CyPD and the PTP represent promising therapeutic targets for neuroprotection in multiple sclerosis.